Reversion of autocrine transformation by a dominant negative platelet-derived growth factor mutant.
about
Gene therapy for carcinoma of the breast: Genetic ablation strategiesActions of heparin that may affect the malignant process.Novel chemotherapeutic agents for the treatment of glioblastoma multiforme.Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials.An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cellsPhosphorylation of tyrosine 720 in the platelet-derived growth factor alpha receptor is required for binding of Grb2 and SHP-2 but not for activation of Ras or cell proliferation.Inhibition of platelet-derived growth factor signalling induces autophagy in malignant glioma cellsSuppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor.Growth factor receptors signaling in glioblastoma cells: therapeutic implications.Characterization of growth factor responsiveness and alterations in growth factor homeostasis involved in the tumorigenic conversion of mouse oval cells.Platelet-derived growth factor-dependent cellular transformation requires either phospholipase Cgamma or phosphatidylinositol 3 kinase.Involvement of loop 2 of platelet-derived growth factor-AA and -BB in receptor binding.Gene therapy strategies for carcinoma of the breast.Loop III region of platelet-derived growth factor (PDGF) B-chain mediates binding to PDGF receptors and heparin.Platelet-derived growth factor-dependent association of the GTPase-activating protein of Ras and Src.A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability.In vitro cholesteatoma growth and secretion of cytokines
P2860
Q24797953-8D79488B-4DBA-4777-BCC2-F389C5B8579CQ33534337-868A914F-5FF5-4C8B-84D2-874D6C9D756CQ35594029-12EE61FF-445B-4EFC-922D-8F0CDE3EE868Q36181201-443B3AB0-5D91-4A11-B6FD-F28E8E4C492EQ36477682-15A8D269-0380-4666-8368-DC643D738EABQ36564274-5740372B-FB5E-4719-A4E6-E91AF6E2AD22Q36694692-8565E851-8398-4468-AC96-BBE3B65186D6Q37408097-CAF8CBA1-0ECD-4A4B-B359-E01C13C3E682Q39910645-657DC8D6-66F5-479F-98CA-9E6C4DF57542Q41059629-14D2E218-011A-4460-ABEC-A41C2039DE20Q41116788-05649617-3CDD-4C78-847A-2AD3F30295A0Q41385508-B480CF24-B0ED-405C-B3BF-B167C736B4FAQ41540501-D3C61C4A-033A-4F98-9620-2EC57A77F778Q41833105-B6F96667-5088-47E8-A9DC-4A0400F907CAQ42995228-61B87641-ACE3-4AD6-88E9-848CC8D6DA11Q46918660-9D52B2E9-E541-4D87-A90B-3137D290475EQ58274650-1A72A0D3-0F02-4CA6-B2BB-2C4D87F60589
P2860
Reversion of autocrine transformation by a dominant negative platelet-derived growth factor mutant.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Reversion of autocrine transfo ...... -derived growth factor mutant.
@en
type
label
Reversion of autocrine transfo ...... -derived growth factor mutant.
@en
prefLabel
Reversion of autocrine transfo ...... -derived growth factor mutant.
@en
P2093
P2860
P356
P1476
Reversion of autocrine transfo ...... -derived growth factor mutant.
@en
P2093
Andersson M
Vassbotn FS
P2860
P304
P356
10.1128/MCB.13.7.4066
P407
P577
1993-07-01T00:00:00Z